14-day Premium Trial Subscription Try For FreeTry Free
$4.33
-0.160 (-3.56%)
At Close: May 02, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $0.265 $5.95 Thursday, 2nd May 2024 WINT stock ended at $4.33. This is 3.56% less than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 10.71% from a day low at $4.20 to a day high of $4.65.
90 days $0.265 $5.95
52 weeks $0.265 $5.95

Historical Windtree Therapeutics Inc prices

Date Open High Low Close Volume
Feb 22, 2023 $0.225 $0.381 $0.211 $0.250 160 656 735
Feb 21, 2023 $0.160 $0.180 $0.140 $0.170 5 748 331
Feb 17, 2023 $0.145 $0.150 $0.140 $0.141 286 318
Feb 16, 2023 $0.149 $0.150 $0.140 $0.145 553 552
Feb 15, 2023 $0.148 $0.155 $0.145 $0.149 1 149 856
Feb 14, 2023 $0.157 $0.157 $0.151 $0.155 220 884
Feb 13, 2023 $0.156 $0.158 $0.150 $0.157 207 547
Feb 10, 2023 $0.150 $0.157 $0.150 $0.156 454 818
Feb 09, 2023 $0.168 $0.169 $0.150 $0.151 989 222
Feb 08, 2023 $0.172 $0.172 $0.160 $0.165 781 157
Feb 07, 2023 $0.180 $0.180 $0.167 $0.175 490 217
Feb 06, 2023 $0.170 $0.186 $0.160 $0.180 1 482 208
Feb 03, 2023 $0.170 $0.172 $0.161 $0.168 880 007
Feb 02, 2023 $0.165 $0.166 $0.161 $0.166 754 105
Feb 01, 2023 $0.165 $0.165 $0.155 $0.162 556 007
Jan 31, 2023 $0.160 $0.165 $0.151 $0.160 651 713
Jan 30, 2023 $0.169 $0.169 $0.150 $0.158 1 239 523
Jan 27, 2023 $0.164 $0.170 $0.155 $0.164 666 701
Jan 26, 2023 $0.180 $0.180 $0.154 $0.164 718 702
Jan 25, 2023 $0.175 $0.175 $0.160 $0.169 856 413
Jan 24, 2023 $0.170 $0.182 $0.164 $0.170 2 209 002
Jan 23, 2023 $0.170 $0.172 $0.160 $0.170 844 490
Jan 20, 2023 $0.160 $0.175 $0.140 $0.162 5 349 135
Jan 19, 2023 $0.219 $0.222 $0.204 $0.218 149 614
Jan 18, 2023 $0.240 $0.240 $0.220 $0.220 169 600
Click to get the best stock tips daily for free!

About Windtree Therapeutics Inc

Windtree Therapeutics Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF,... WINT Profile

Golden Star

Ticker Date Change Price
HRB Apr 29 1.00% $47.23
LYG Apr 29 0.391% $2.56
ORA Apr 29 1.95% $64.48
ETSY Apr 26 3.43% $67.43
DHT Apr 24 0.98% $11.28
LPLA Apr 19 1.10% $262.59
MLI Apr 19 7.29% $52.28
PFLT Apr 18 1.33% $11.25
DOOR Apr 18 0.94% $131.39
OCSL Apr 17 0.360% $19.43
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT